Overview

SinTilimab After Radiation (STAR Study)

Status:
Recruiting

Trial end date:
2023-04-15

Target enrollment:

Participant gender:

Summary

This is a single-arm phase II study, to investigator the efficacy and safety of sintilimab after radiation in advanced NSCLC, who had failed first line systemic therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Peking Union Medical College Hospital